BIN1
- Known as:
- BIN1
- Catalog number:
- Y214053
- Product Quantity:
- 200ul
- Category:
- -
- Supplier:
- ABM
- Gene target:
- BIN1
Related genes to: BIN1
- Gene:
- BIN1 NIH gene
- Name:
- bridging integrator 1
- Previous symbol:
- AMPHL
- Synonyms:
- SH3P9, AMPH2
- Chromosome:
- 2q14.3
- Locus Type:
- gene with protein product
- Date approved:
- 2000-05-19
- Date modifiied:
- 2019-04-23
Related products to: BIN1
Related articles to: BIN1
- Amyloid-beta (Aβ) plaque formation and tauopathy are two of several hallmarks of Alzheimer's disease (AD), a neurodegenerative disease. AD's widely known pathological hallmarks include extracellular amyloid-β deposition, neurofibrillary tangles (NFTs) composed of hyperphosphorylated tau protein, synaptic dysfunction, neuroinflammation, and cognitive decline. These pathological hallmarks can be explained at the neurochemical level as a loss of biochemical homeostasis in the brain. Dysregulated kinase-phosphatase signalling, altered post-translational modifications, and disrupted synaptic neurochemistry eventually push tau protein towards its pathological aggregation-prone form. Among these hallmarks, recent research has found that tau pathology plays a major role in neurodegeneration and cognitive decline. Tau protein typically acts as a microtubule-stabilizing protein that helps maintain neuronal structure. In AD, pathological hyperphosphorylation, post-translational modifications, and redistribution of tau trigger its dysfunction and cytotoxicity. Pathological tau protein accumulates in neurons and undergoes a series of changes that include hyperphosphorylation, aberrant post-translational modifications, missorting, aggregation, fibrillization, and seeding as it spreads between cells. Mutations in APP, PSEN1, and PSEN2 can have downstream effects on tau pathology. Variants in APOE, BIN1, PICALM, CD2AP, and TREM2 also influence tau pathology through cellular pathways including lipid metabolism, endocytic trafficking, proteostasis, and synaptic and neuroimmune mechanisms. These findings support a model in which tau dysfunction results from the convergence of molecular aberrations and genetic susceptibility within a pathological network involving amyloid-β, neuroinflammation, and synaptic failure. This review summarizes tau molecular and cellular mechanisms of tau dysfunction in AD, genetic factors regulating tau pathology, and emerging therapeutic approaches to mitigate tau-mediated neurodegeneration. - Source: PubMed
Publication date: 2026/08/13
Sura SreenivasuluJagadeesan SaravananMoklas Mohamad Aris MohdMasrudin Siti SalehaDandala Krishna Chaitanya ReddyJudson John PaulMohdNor Nurul Huda - Collective endothelial migration during vascular development relies on dynamic cell-cell contacts, yet how the junctions between leader and follower cells are organized remains poorly understood. Using Cryo-SIM followed by FIB-SEM, we investigated the nanoscale 3D ultrastructure of asymmetric adherens junctions (AAJs), revealing a wide spectrum of membrane folds at the contact interface between migrating endothelial cells. By performing a junction localization screen, we identified a variety of membrane curvature-sensing BAR domain proteins selectively enriched at AAJs. Among these, BIN1 and SNX9 emerged as novel regulators of front-to-rear polarity in follower cells during endothelial collective migration. The spatiotemporal recruitment of these individual BAR proteins associated with distinct phases of AAJ remodeling. Furthermore, depletion of SNX9 disturbed VE-cadherin dynamics, endothelial cell directionality, and sheet migration in the common cardinal vein of zebrafish. These findings highlight junctional nanoscale membrane curvatures as hubs for the spatiotemporal recruitment of a repertoire of BAR proteins to remodel AAJs and guide collective endothelial migration during vascular development. - Source: PubMed
Publication date: 2026/07/27
Janssen Verade Kraker HannahAaron Jesse Sde Haan Annettde Heer IrisKhuon SatyaDa Silva JasonDriessen Amber J MChew Teng-LeongTan Josephine M ELagendijk Anne KAngulo-Urarte AnaHuveneers Stephan - Alzheimer's disease (AD), Parkinson's disease (PD) and Lewy body dementia (LBD) overlap clinically, pathologically and genetically, complicating interpretation of cross-disorder genome-wide association study (GWAS) signals. - Source: PubMed
Publication date: 2026/07/02
Zhang YingZhang ZhishuaiQiu ShizhengHu Yang - Synapse loss correlates with cognitive decline in neurodegenerative diseases like late-onset Alzheimer's disease. We developed a semi-automated workflow to quantify synapse loss in primary mouse neurons. The protocol includes culturing neurons on coverslips, using short hairpin RNA (shRNA)-expressing lentivirus, maintaining cultures, and labeling excitatory and inhibitory presynaptic markers by immunofluorescence. Image acquisition and analysis using Fiji/ComDet macros enable region of interest selection, neurite length measurement, puncta detection, and quantification of synapse density, size, and intensity following Bin1 knockdown. For complete details on the use and execution of this protocol, please refer to Barata et al.. - Source: PubMed
Publication date: 2026/07/03
Barata Mariana AGuimas Almeida Cláudia - Understanding the genetic foundations of dementia is critical to unraveling its complex molecular basis. Given that a clinical diagnosis of Alzheimer's disease (AD) dementia often results from interplay between multiple underlying neuropathologic co-morbidities, previous genome-wide association studies (GWAS) of clinically diagnosed AD are restricted in their ability to translate genetic associations to potential targeted therapeutics. The current study seeks to address these limitations by presenting the largest GWAS to date (n = 12,509) of neuropathologic hallmarks of AD and AD related dementias (ADRDs). We further performed a candidate-variant analysis using loci previously identified in GWAS of clinically diagnosed AD dementia and Parkinson's disease (PD). Finally, we conducted heritability and genetic correlation analyses using linkage disequilibrium (LD) score regression. We found broad genome-wide significant associations with APOE across AD and ADRDs but not cerebrovascular disease and vascular brain injury. We further identified 12 significant loci across 10 neuropathologic phenotypes, including 5 loci previously implicated in GWAS of clinical AD and ADRDs (variants on BIN1, PICALM/ EED, TMEM106B, GRN, and SNCA/ SNCA-AS1) and 7 novel genome-wide associations (variants on EPHA5, PSMG1, LINC00276, VAPA, LINC00290, DOCK4 and SLAIN2/ SLC10A4). Our analysis of AD and PD clinical candidate variants demonstrated several that were associated with AD neuropathologic change and Lewy body disease, as well as substantial overlap with neuropathologic lesions other than the primary neuropathologic hallmarks of these diseases. Heritability analyses demonstrated heritability that was high for amyloid plaques (78%) relative to prior clinical AD heritability analyses, intermediate for TDP-43 inclusions (41%), and low for remaining AD and ADRD pathologic features. This study underscores the importance of investigating the underlying neuropathologic hallmarks of AD and ADRDs as a step toward refining the translation of genetic associations to biomarker interpretation and development of targeted therapeutics. - Source: PubMed
Publication date: 2026/06/29
Cholerton BrennaGodrich DanaPasteris JeremyRivero JoeMartin Eden RKunkle Brian WNaj Adam CHamilton-Nelson Kara LWang HuiLee Wan-PingDumitrescu LoganHohman Timothy JMayeux RichardLarson Eric BCrane Paul KKeene C DirkLatimer Caitlin SMukherjee ShubhabrataKofler Julia KKamboh M IlyasBennett David AMolina-Porcel LauraCuccaro MichaelPericak-Vance Margaret ARundek TatjanaScott William KKukull WalterSchellenberg Gerard Beecham Gary WMontine Thomas J